BiotechTube

Ceralasertib + Olaparib + Durvalumab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clear Cell Renal Cell Carcinoma

Conditions

Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer

Trial Timeline

Jan 17, 2019 → Mar 31, 2028

NCT ID
NCT03682289

About Ceralasertib + Olaparib + Durvalumab

Ceralasertib + Olaparib + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Clear Cell Renal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03682289. Target conditions include Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm.

What happened to similar drugs?

3 of 13 similar drugs in Clear Cell Renal Cell Carcinoma were approved

Approved (3) Terminated (1) Active (9)
✅CefiderocolShionogiApproved
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
✅carbamazepine oxcarbazepineNovartisApproved
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
🔄Carboplatin + Cediranib Maleate + Gemcitabine + Gemcitabine Hydrochloride + Olaparib + Paclitaxel + Pegylated Liposomal Doxorubicin HydrochlorideAstraZenecaPhase 3
🔄Volrustomig + Casdatifan + Nivolumab + IpilimumabAstraZenecaPhase 3
🔄HFO-1234ze(E) + HFA-134aAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04065269Phase 2Active
NCT03682289Phase 2Recruiting

Competing Products

20 competing products in Clear Cell Renal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Pembrolizumab + CabozantinibGenenta SciencePhase 1/2
14
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
CefiderocolShionogiApproved
50
fospropofol + fospropofol + fospropofol + fospropofolEisaiPre-clinical
18
lenvatinib + everolimusEisaiPhase 2
35
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
LY2510924 + SunitinibEli LillyPhase 2
27
Abemaciclib + MK-6482Eli LillyPhase 1
29
nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
43
ABBV-8E12 + Placebo solution for IV infusion on Day 15AbbViePhase 2
27
Placebo + ABBV-8E12AbbViePhase 2
27
ABBV-8E12AbbViePhase 1
29
Savolitinib + MEDI4736 + TremelimumabAstraZenecaPhase 2
35
Carboplatin + Cediranib Maleate + Gemcitabine + Gemcitabine Hydrochloride + Olaparib + Paclitaxel + Pegylated Liposomal Doxorubicin HydrochlorideAstraZenecaPhase 3
44
AZD8701 + DurvalumabAstraZenecaPhase 1
29
AZD2014 + EverolimusAstraZenecaPhase 2
27
Volrustomig + Casdatifan + Nivolumab + IpilimumabAstraZenecaPhase 3
44
HFO-1234ze(E) + HFA-134aAstraZenecaPhase 3
40
Pembrolizumab plus denosumabMerckPhase 2
31
MK-3475 + Bevacizumab + MK-3475 + BevacizumabMerckPhase 1/2
32